Current and Future Trends in Myeloproliferative Neoplasms
Episodes
All
EP. 1: Myeloproliferative Neoplasms: Essential Thrombocythemia
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.
EP. 2: Managing Patients with Essential Thrombocythemia
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
EP. 3: Myeloproliferative Neoplasms: Polycythemia Vera
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
EP. 4: Treatment Options for Polycythemia Vera
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center An overview of the treatment options for patients with polycythemia vera.
EP. 5: PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
EP. 6: Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
EP. 7: Myeloproliferative Neoplasms: Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
EP. 8: Risk Stratification for Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
EP. 9: Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.
EP. 10: New JAK Inhibitors in Myelofibrosis Treatment
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.
EP. 11: Efficacy and Safety of JAK Inhibitors for Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
EP. 12: Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
EP. 13: Novel Agents Under Investigation for Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
EP. 14: Management of Accelerated Phase Myeloproliferative Neoplasms
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
EP. 15: Clinical Scenario: A 67-Year-Old with Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
EP. 16: Myelofibrosis Treatment Approaches after Disease Progression
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
EP. 17: Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
EP. 18: The Future of Myeloproliferative Neoplasm Treatment
ByRami Komrokji, MD,Ruben Mesa, MD,Jeanne M. Palmer, MD,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center The panelists conclude their discussion by highlighting investigational agents to look forward to.
